PLAT and intracranial hemorrhage: The larger, multicenter SEATTLE II study confirmed significant reductions in RV dilatation and pulmonary-artery pressure using 24 mg total tPA, reporting a 10% major-bleeding rate but no intracranial hemorrhage (Piazza et al., 2015).